Psychedelic drug development is advancing quickly, but clinical progress often stalls due to small datasets, regulatory uncertainty and a lack of objective biomarkers. What if neuroimaging could change that, offering a data-driven foundation for more reliable, reproducible development?
This webinar is designed for researchers, clinical developers and investors looking to accelerate psychedelic therapy programs with scientifically grounded insights. Discover how advanced neuroimaging techniques, such as PET and fMRI, and other multimodal approaches, are clarifying mechanisms of action, validating biomarkers and guiding precision dosing and patient stratification.
Join the featured speaker to explore:
- How neuroimaging is uncovering unique neuroplasticity and connectivity effects linked to therapeutic outcomes
- Real-world examples of imaging data informing smarter trial designs and patient selection
- Practical strategies for integrating imaging insights into regulatory submissions and clinical decision-making
Register for this webinar to see how neuroimaging can transform psychedelic drug development, reduce risk, improve study design and help bring safe and effective treatments.
Speaker
Matthew Wall, PhD, Associate Director of Translational MRI, Perceptive
Dr. Matthew Wall is a Neuroscientist and Psychologist with expertise in functional MRI and psychopharmacology. He leads translational MRI efforts at Perceptive and holds an honorary academic post at Imperial College London. His research explores how psychedelics like psilocybin and LSD affect brain function, with broader interests in cannabis, sex hormones and fMRI methods. He has held senior imaging roles at Perceptive and Imanova and authored over 90 publications. He is the Editor of the forthcoming book, Pharmacological fMRI: Methods and Applications (2025), which bridges neuroimaging techniques with clinical and drug development applications.
Message PresenterWho Should Attend?
This session is for scientific, clinical and strategic leaders in psychedelic therapy development who need to leverage neuroimaging to generate stronger data, reduce risk and accelerate clinical progress. Ideal attendees include:
- Chief Scientific Officers (CSOs) and Heads of R&D seeking data-driven approaches to de-risk development programs
- Translational Leads and Clinical Scientists exploring biomarkers for patient stratification or dosing optimization
- Clinical Development and Regulatory Affairs leaders looking for objective markers to strengthen submissions
- Business Development or Strategy Directors evaluating investments in psychedelic or CNS-focused programs
- Researchers and Program Managers advancing first-generation or second-generation psychedelic compounds toward clinical studies
- Investors or decision-makers seeking insight into the science driving next-generation psychedelic therapies
What You Will Learn
Attendees will learn:
- How neuroimaging technologies like PET, fMRI and multimodal approaches provide objective insights into brain mechanisms of psychedelic therapies
- How imaging biomarkers can validate clinical outcomes, support regulatory submissions and reduce the impact of placebo or expectancy effects
- Why neuroimaging is critical for optimizing dosing strategies, patient stratification and trial design in psychedelic drug development
- A practical framework for integrating neuroimaging into preclinical and clinical workflows to accelerate development and improve decision-making
Xtalks Partner
Perceptive Discovery
Perceptive Discovery bridges the gap between preclinical insights and early clinical success, providing the expertise and high-quality data needed to advance innovation with confidence. With deep expertise in advanced imaging, radiochemistry, and translational science, we specialize in supporting drug development programs across CNS, oncology, and radioligand therapy. Our integrated approach combines rigorous scientific analysis, state-of-the-art imaging platforms, and multidisciplinary expertise to deliver data that drives smarter decisions, reduces risk, and accelerates timelines from preclinical to first-in-human studies.
You Must Login To Register for this Free Webinar
Already have an account? LOGIN HERE. If you don’t have an account you need to create a free account.
Create Account